Reliance on HAL as the main product and on approval and insurance systems in each country
First written in FY2016. 7 of 8 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2018: 9 of 45 companies on the "Worse" side.
36 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The Group's main product is HAL®, and revenue related to HAL® accounted for the majority of the Group's revenue in the current consolidated fiscal year. The Group expects HAL® to remain its main source of revenue for the foreseeable future, but changes in the laws and regulations or healthcare policies of individual countries, or delays in establishing insurance systems such as medical insurance, could affect the Group's business and profitability.」
The company continues to disclose its reliance on HAL-related revenue and on the laws and regulations, healthcare policies and insurance systems of individual countries. - FY2024-Q3RestatedAnnual report
「As revenue from a single product or service category to external customers exceeds 90% of revenue in the consolidated income statement, this information has been omitted.」
The company continues to disclose that a single product or service category accounts for more than 90% of revenue from external customers. - FY2024-Q2RestatedAnnual report
「As revenue from a single product or service category to external customers exceeds 90% of revenue in the consolidated income statement, this information has been omitted.」
The company continues to disclose that a single product or service category accounts for more than 90% of revenue from external customers. - FY2020-Q2RestatedAnnual report
「As revenue from a single product or service category to external customers exceeds 90% of the consolidated income statement total, this information has been omitted.」
The company discloses that a single product or service category accounts for more than 90% of revenue from external customers, quantitatively demonstrating the concentration of products and services. - FY2019RestatedAnnual report
「The Group's main product is HAL®, and revenue related to HAL® accounted for the majority of the Group's revenue in the current consolidated fiscal year. The Group expects HAL® to remain a source of revenue for the foreseeable future, but changes in the laws and regulations or healthcare policies of individual countries, or delays in establishing insurance systems such as medical insurance, could affect the Group's business and profitability.」
The company continues to disclose its reliance on HAL-related revenue and on the laws and regulations, healthcare policies and insurance systems of individual countries. - FY2018RestatedAnnual report
「The Group's main product is HAL®, and in the fiscal year ended March 2018, revenue related to HAL® accounted for the majority of the Group's revenue. The Group expects HAL® to remain a source of revenue for the foreseeable future, but changes in the laws and regulations or healthcare policies of individual countries, or delays in establishing insurance systems such as medical insurance, could affect the Group's business and profitability.」
The company reiterates that HAL-related revenue accounted for the majority of revenue in the fiscal year ended March 2018 and is expected to remain a source of revenue for the foreseeable future, as well as its reliance on approval and insurance systems. - FY2017RestatedAnnual report
「The Group's main product is HAL®, and in the fiscal year ended March 2017, revenue related to HAL® accounted for the majority of the Group's revenue. The Group expects HAL® to remain a source of revenue for the foreseeable future.」
HAL-related revenue continued to account for the majority of revenue in the fiscal year ended March 2017, and the company reiterates its expectation that HAL will remain a source of revenue for the foreseeable future. - FY2016First statedAnnual report
「The Group's main product is HAL®, and in the fiscal year ended March 2016, revenue related to HAL® accounted for the majority of the Group's revenue.」
The company indicates its revenue dependence on HAL as its main product and states that US approval, delays in establishing regulatory, healthcare policy and insurance systems in various countries, and other factors could affect profitability.